The company states: “Eli Lilly (LLY) and Scorpion Therapeutics announced a definitive agreement for Lilly to acquire Scorpion’s PI3Kalpha inhibitor program STX-478. STX-478 is a once-daily ...

Eli Lilly (LLY) and Scorpion Therapeutics announced a definitive agreement for Lilly to acquire Scorpion’s PI3Kalpha ...

Lilly will acquire our mutant-selective PI3Kα inhibitor program, led by STX-478, a promising, next-generation treatment currently in Phase 1/2 trials for breast cancer and other advanced solid ...

STX-478 is under clinical development by Scorpion Therapeutics and currently in Phase II for Endometrial Cancer. According to GlobalData, Phase II drugs for Endometrial Cancer have a 22% phase ...

Potential antitrust deregulation could foster a more favourable environment for larger M&A deals in 2025, though skepticism ...

Meanwhile, Lilly announced plans to acquire Scorpion Therapeutics’ PI3Kα inhibitor STX-478 for $2.5 billion, with its non-PI3Kα drugs spun off into a new company. STX-478 is currently in Phase ...

Three recent big-ticket M&A deals have raised expectations the global biotech sector is recovering from its two-year slump.

The acquisition will expand Lilly's oncology pipeline with STX-478, the differentiated and potentially best-in-class, mutant-selective PI3Kα inhibitor currently in a Phase 1/2 clinical trial STX-478 ...

The acquisition will expand Lilly's oncology pipeline with STX-478, the differentiated and potentially best-in-class, mutant-selective PI3Kα inhibitor currently in a Phase 1/2 clinical trial STX ...

The acquisition will expand Lilly's oncology pipeline with STX-478, the differentiated and potentially best-in-class, mutant-selective PI3Ka inhibitor currently in a Phase 1/2 clinical trial STX ...